Literature DB >> 31201679

Clinical and molecular characteristics of thirty NF1 variants in Chinese patients with neurofibromatosis type 1.

Wen Wang1, Weibing Qin2, Hongsong Ge3, Xiangsheng Kong4, Chao Xie5, Yunge Tang6, Ming Li7.   

Abstract

Neurofibromatosis type 1 (NF1) is a common autosomal dominant tumor-predisposition disorder that mainly impacts the nervous system and skin. Since the full clinical presentation of NF1 depends on age, it can be difficult to make an early and definite diagnosis in paediatric patients without family history who only exhibited multiple cafè-au-lait spots, highlighting the need for mutational analysis. A combination of techniques was conducted in 30 families with NF1, including multi-gene panels, direct sequencing, cDNA sequencing and multiplex ligation-dependent probe amplification. Thirty variants were identified in 36 patients from the 30 families, among which ten variants were novel. As a result, we confirmed that the combination of techniques were highly accurate and sensitive for identifying pathogenic variants in patients clinically suspected of having NF1, in particular, for patients who only present with multiple cafè-au-lait spots.

Entities:  

Keywords:  Multi-gene panel; Multiplex ligation-dependent probe amplification; NF1; Neurofibromatosis type 1; cDNA sequencing

Mesh:

Year:  2019        PMID: 31201679     DOI: 10.1007/s11033-019-04888-3

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  47 in total

Review 1.  NF1 tumor suppressor gene function: narrowing the GAP.

Authors:  K Cichowski; T Jacks
Journal:  Cell       Date:  2001-02-23       Impact factor: 41.582

2.  A nonsense mutation at Arg-1947 in the NF1 gene in a case of neurofibromatosis type 1 in a Korean patient.

Authors:  K C Park; H O Choi; K H Park; K H Kim; H C Eun
Journal:  J Hum Genet       Date:  2000       Impact factor: 3.172

3.  Two independent mutations in a family with neurofibromatosis type 1 (NF1).

Authors:  A Klose; H Peters; S Hoffmeyer; A Buske; A Lüder; D Hess; R Lehmann; P Nürnberg; S Tinschert
Journal:  Am J Med Genet       Date:  1999-03-05

4.  Use of the national institutes of health criteria for diagnosis of neurofibromatosis 1 in children.

Authors:  K DeBella; J Szudek; J M Friedman
Journal:  Pediatrics       Date:  2000-03       Impact factor: 7.124

5.  Mutations affecting mRNA splicing are the most common molecular defects in patients with neurofibromatosis type 1.

Authors:  E Ars; E Serra; J García; H Kruyer; A Gaona; C Lázaro; X Estivill
Journal:  Hum Mol Genet       Date:  2000-01-22       Impact factor: 6.150

6.  Somatic NF1 mutation spectra in a family with neurofibromatosis type 1: toward a theory of genetic modifiers.

Authors:  Verena Wiest; Ingrid Eisenbarth; Claudia Schmegner; Winfrid Krone; Günter Assum
Journal:  Hum Mutat       Date:  2003-12       Impact factor: 4.878

7.  Minor lesion mutational spectrum of the entire NF1 gene does not explain its high mutability but points to a functional domain upstream of the GAP-related domain.

Authors:  R Fahsold; S Hoffmeyer; C Mischung; C Gille; C Ehlers; N Kücükceylan; M Abdel-Nour; A Gewies; H Peters; D Kaufmann; A Buske; S Tinschert; P Nürnberg
Journal:  Am J Hum Genet       Date:  2000-03       Impact factor: 11.025

8.  Preferential mutation of the neurofibromatosis type 1 gene in paternally derived chromosomes.

Authors:  K Stephens; L Kayes; V M Riccardi; M Rising; V P Sybert; R A Pagon
Journal:  Hum Genet       Date:  1992-01       Impact factor: 4.132

9.  Ten novel mutations in the human neurofibromatosis type 1 (NF1) gene in Italian patients.

Authors:  Paola Origone; Alessandro De Luca; Carlo Bellini; Anna Buccino; Rita Mingarelli; Simona Costabel; Carmen La Rosa; Cecilia Garrè; Domenico A Coviello; Franco Ajmar; Bruno Dallapiccola; Eugenio Bonioli
Journal:  Hum Mutat       Date:  2002-07       Impact factor: 4.878

10.  Recurrent mutations in the NF1 gene are common among neurofibromatosis type 1 patients.

Authors:  E Ars; H Kruyer; M Morell; E Pros; E Serra; A Ravella; X Estivill; C Lázaro
Journal:  J Med Genet       Date:  2003-06       Impact factor: 6.318

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.